Physician profile
Rita E Meadows
NPI 1093928756
$7,971.13
in general payments reported to CMS, 2019-2025
47 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,065 · 2022: $3,299 · 2023: $1,480 · 2024: $20.30 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,034.79 | 2021-2025 | |
| Novo Nordisk INC | $1,021.71 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $540.75 | 2021-2023 | Spravato |
| Astrazeneca Pharmaceuticals LP | $518.07 | 2021-2022 | |
| Amgen INC. | $372.94 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.38 | 2021-2023 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $306.39 | 2021-2023 | Emgality, Jardiance |
| Novartis Pharmaceuticals Corporation | $304.68 | 2021-2023 | |
| Dexcom, INC. | $268.53 | 2021-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $261.06 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $235.74 | 2021-2023 | Trelegy Ellipta |
| Avanir Pharmaceuticals, INC. | $213.83 | 2021-2022 | |
| Pfizer INC. | $204.07 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $182.63 | 2022 | |
| Amarin Pharma, INC. | $177.40 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.